Published in Curr Opin Struct Biol on June 17, 2016
Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care? J Clin Aesthet Dermatol (2016) 0.75
Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol (2005) 5.97
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol (2008) 3.71
Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol (2012) 3.41
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res (2014) 2.66
Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53
The immune epitope database (IEDB) 3.0. Nucleic Acids Res (2014) 2.50
Production of functional chimaeric mouse/human antibody. Nature (1985) 2.35
Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J (2000) 2.00
The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs (2010) 1.86
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 1.68
RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS One (2011) 1.59
Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself (2010) 1.45
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol (2005) 1.42
What's fueling the biotech engine-2012 to 2013. Nat Biotechnol (2014) 1.33
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood (2001) 1.26
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proc Natl Acad Sci U S A (2014) 1.23
Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res (2011) 1.22
OSPREY: protein design with ensembles, flexibility, and provable algorithms. Methods Enzymol (2013) 1.20
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A (2011) 1.18
A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther (2005) 1.17
In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther (2014) 1.15
The immunogenicity of therapeutic proteins. Discov Med (2010) 1.15
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol (2013) 1.15
Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals (2011) 1.12
Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol (2004) 1.11
Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource. Clin Dev Immunol (2013) 1.09
Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics (2010) 1.08
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev (2009) 1.07
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost (2005) 1.07
Structure-guided deimmunization of therapeutic proteins. J Comput Biol (2013) 1.04
Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther (2014) 1.03
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost (2002) 1.03
Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A (2014) 0.99
Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions. J Bioinform Comput Biol (2011) 0.98
PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel (2013) 0.97
Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel (2012) 0.95
A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments. Proteins (2011) 0.94
Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz) (2012) 0.94
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation (1996) 0.93
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood (2000) 0.93
Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods (2015) 0.92
Structure-based redesign of proteins for minimal T-cell epitope content. J Comput Chem (2013) 0.92
Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg (2011) 0.90
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer (2004) 0.89
Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads. Biotechnol Bioeng (2015) 0.88
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today (2014) 0.87
Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods Enzymol (2012) 0.86
Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate. Cell Mol Life Sci (2014) 0.85
Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate. PLoS Comput Biol (2015) 0.84
Generation and utility of genetically humanized mouse models. Drug Discov Today (2013) 0.83
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol (2016) 0.83
Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development. Toxins (Basel) (2015) 0.83
Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo. Chem Biol (2015) 0.83
A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective. J Immunol Methods (2015) 0.83
Immunogenicity of Therapeutic Protein Aggregates. J Pharm Sci (2016) 0.82
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity. PLoS One (2015) 0.82
Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction. Circulation (1996) 0.82
OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes. PLoS One (2014) 0.82
Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody. PLoS One (2015) 0.82
Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance. Mol Ther Methods Clin Dev (2015) 0.81
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. J Pharm Sci (2016) 0.81
Antibody humanization by structure-based computational protein design. MAbs (2015) 0.80
Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res (2013) 0.80
Tabhu: tools for antibody humanization. Bioinformatics (2014) 0.79
Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity. Sci Rep (2014) 0.79
Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. Protein Eng Des Sel (2013) 0.79
Engineering less immunogenic and antigenic FVIII proteins. Cell Immunol (2015) 0.79
Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products. Cell Immunol (2015) 0.79
DNA shuffling of uricase gene leads to a more "human like" chimeric uricase with increased uricolytic activity. Int J Biol Macromol (2015) 0.78
Critical assessment of human antibody generation in humanized mouse models. J Immunol Methods (2014) 0.78
Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. Biol Chem (2005) 0.78
Engineering antigen-specific immunological tolerance. Curr Opin Immunol (2015) 0.77
Directed evolution of chemotaxis inhibitory protein of Staphylococcus aureus generates biologically functional variants with reduced interaction with human antibodies. Protein Eng Des Sel (2009) 0.77
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget (2016) 0.77
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. J Pharm Sci (2016) 0.76
Computationally driven antibody engineering enables simultaneous humanization and thermostabilization. Protein Eng Des Sel (2016) 0.76
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice. J Biol Chem (2013) 0.76